Drug maker Lupin launches chronic angina treatment drug in the US
"Products like Ranolazine bring significant savings to US consumers and are a key part of our vision to bring exclusive high quality, affordable medicines to the market, he added. Shares of Lupin were trading 0.29 per cent up at Rs 769.95 apiece on BSE.
Quoting IQVIA MAT December 2018 data, Lupin said Ranolazine ER tablets, 500 mg and 1,000 mg had an annual sales of approximately USD 945 million in the US. Reuters